Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04196101
Other study ID # EDP 938-102
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date January 22, 2020
Est. completion date January 4, 2022

Study information

Verified date September 2023
Source Enanta Pharmaceuticals, Inc
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This was a randomized, double-blind, placebo-controlled, multicentre, phase 2 study to evaluate the efficacy, safety and tolerability of orally administered EDP-938 in adults with RSV infection.


Description:

Subjects (aged 18 to 75 years, inclusive) with up to 48 hours of upper respiratory tract infection (URTI) symptoms who tested positive for respiratory syncytial virus (RSV) and negative for influenza virus by rapid testing (ie, Rapid Viral Screen). Subjects with stable asthma or chronic obstructive pulmonary disease (COPD) were allowed in the study. Eighty-two (82) subjects were enrolled in this Phase 2b, randomized, double-blind, placebo-controlled, multicentre study of EDP-938 administered orally for the treatment of acute URTI with confirmed RSV infection in ambulatory adult subjects. For each subject, the duration of study participation was approximately 2 weeks and consisted of 3 periods: Screening (occurs on Day1), Treatment (5 days), and Follow-up (9 days after last dose).


Recruitment information / eligibility

Status Completed
Enrollment 82
Est. completion date January 4, 2022
Est. primary completion date January 4, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - An informed consent document must be signed and dated by the subject - Male or female individuals aged 18 to 75 years, inclusive. - Up to 48 hours of URTI symptoms with at least one of the following symptoms: Nasal discharge, nasal congestion, malaise/tiredness, headache, sinus congestion, sneezing, sore throat, hoarseness, cough, shortness of breath, respiratory wheeze, earache, and/or symptoms of fever. - Positive for RSV infection and negative for influenza virus based on rapid diagnostic. - Must be willing and able to adhere to the study assessments, visit schedules, prohibitions, and restrictions, as described in this protocol. Exclusion Criteria: - SARS-CoV-2 positive within 28 days of Screening or at Screening following signature of full ICF. - Clinical evidence of a lower respiratory tract infection, as determined by the Investigator. - Anticipated need for hospitalization or emergency room care within 24 hours of Screening. - Receipt of systemic antiviral, antibacterial, antifungal, or antimycobacterial therapy within 7 days of Screening and for the duration of the study - Awareness of concomitant respiratory infections that are viral (other than RSV), bacterial, or fungal, including systemic bacterial or fungal infections, within 7 days of Screening. - Frailty scale score =4 at Screening. - History of chronic liver disease (eg, hemochromatosis, Wilson's disease, alpha-1 antitrypsin deficiency, autoimmune hepatitis, nonalcoholic steatohepatitis, and/or alcoholic liver disease); a history of biliary disease (eg, primary sclerosing cholangitis, cholecystitis, choledocholithiasis); or a history of portal hypertension. A diagnosis of hepatic steatosis (fatty liver) is not exclusionary. - Heart disease: any congenital heart disease, acute or chronic heart failure, ischemic heart disease, congenital long QT syndrome, or any clinical manifestation resulting in QT interval prolongation. - Neurological and neurodevelopmental disorders (including disorders of the brain, spinal cord, peripheral nerve, and muscle, eg, cerebral palsy, epilepsy [seizure disorders], stroke, muscular dystrophy, or spinal cord injury). - Malignant tumor or history of malignancy that may interfere with the aims of the study or a subject completing the study. - Prior receipt or the subject is waiting to receive a bone marrow, stem cell, or solid organ transplantation. - Diagnosis of cystic fibrosis. - Known positive human immunodeficiency virus, active hepatitis A virus infection, chronic hepatitis B virus infection, and/or current or treated hepatitis C virus infection. - Prior or planned ileal resection or bariatric surgery. - Pregnant or nursing female subjects. - History of alcohol addiction or current heavy alcohol use defined as: >14 standard drinks per week and/or =4 standard drinks per occasion for males and >7 standard drinks per week and/or =3 standard drinks per occasion for females. A standard drink is 12 oz of beer (5% alcohol), 5 oz table wine (12% alcohol), or 1.5 oz of spirits (40% alcohol). - Known or suspected, in the opinion of the Investigator, renal disease or renal impairment. - Twelve-lead ECG demonstrating a QT interval corrected for heart rate according to Fridericia (QTcF) that is >500 msec or other clinically relevant abnormalities as judged by the Investigator at Screening. - Use of or intention to use excluded or contraindicated medication(s) or supplements, including any medication known to be a moderate or potent inducer or inhibitor of the cytochrome P450 3A4 enzyme, within 14 days prior to Screening and for the duration of the study. - Receipt of =14 days of systemic immunomodulator therapy (eg, oral corticosteroids) within 3 months of Screening. - Prior to the first dose of study drug and during study participation, the subject has received any vaccine, investigational agent, or biological product within 30 days or 5 times the half-life, whichever is longer. Note: Influenza vaccination within 7 days of Screening is allowed. - Use of St John's wort within 28 days prior to the first dose of study drug and for the duration of the study. - History of or currently experiencing a medical condition or any other finding (including laboratory test results) that, in the opinion of the Investigator, might confound the results of the study; pose an additional risk in administering study drug to the subject; could prevent, limit, or confound the protocol-specified assessments; or deems the subject unsuitable for the study.

Study Design


Intervention

Drug:
EDP-938
Four tablets daily for 5 days
Placebo
Four tablets daily for 5 days

Locations

Country Name City State
Argentina Instituto Medico Platense Buenos Aires
Bulgaria Multiprofile Hospital for Active Treatment Puls Blagoevgrad
Bulgaria Specialized Hospital for Active Treatment of Pneumophthisiatric Diseases - Haskovo EOOD Haskovo
Bulgaria Medical Center Zdrave-1 OOD Kozloduy
Bulgaria Diagnostic and Consulting Center Aleksandrovska EOOD Sofia Sofia-Grad
Bulgaria Medical Center Hera Sofia Sofia-Grad
Bulgaria Medical Center Tara OOD Veliko Tarnovo
New Zealand Lakeland Clinical Trials - Waikato Hamilton
New Zealand Lakeland Clinical Trials Rotorua
Poland Specjalistyczny Osrodek Leczniczo-Badawczy Zbigniew Zegota Ostróda
Poland Alergo-Med Specjalistyczna Przychodnia Lekarska Sp. z.o.o Tarnów Malopolskie
South Africa Clinical Projects Research SA pty Ltd Worcester Western Cape
Ukraine Communal Non-Profit Enterprise City Clinical Hospital #1 of Ivano-Frankivsk City Council Ivano-Frankivs'k Ivano-Frankivsk
Ukraine City Outpatient Clinic #9 Kyiv
Ukraine Limited Liability Company Medical Center Consilium Medical Kyiv
Ukraine Medical Center of LLC Preventclinic Kyiv
Ukraine Municipal Enterprise The 1st City Clinical Hospital of Poltava City Council Poltava Poltavs'ka Oblast
United States Saint Joseph's Clinical Research Anaheim California
United States Pioneer Clinical Research LLC Bellevue Nebraska
United States Central Alabama Research Birmingham Alabama
United States FMC Science Lampasas Texas
United States Clinical Research of South Nevada Las Vegas Nevada
United States Torrance Clinical Research Institute Lomita California
United States Miami Clinical Research - ClinEdge - PPDS Miami Florida
United States Meridian Clinical Research Norfolk Nebraska
United States Cahaba Research Inc. - Birmingham Pelham Alabama
United States Carolina Research Center Shelby North Carolina
United States PMG Research of Wilmington Wilmington North Carolina
United States Progressive Medicine of the Triad, LLC Winston-Salem North Carolina

Sponsors (2)

Lead Sponsor Collaborator
Enanta Pharmaceuticals, Inc PPD

Countries where clinical trial is conducted

United States,  Argentina,  Bulgaria,  New Zealand,  Poland,  South Africa,  Ukraine, 

Outcome

Type Measure Description Time frame Safety issue
Primary Total Symptom Score (TSS) Area Under the Curve (AUC) Assessed by the RSV Symptom Diary, including 13 items assessing the severity of RSV-related signs and symptoms. The diary uses a 4-point scale that consists of grading symptoms on a scale of 0 to 3 for each item, where Grade 0 is Absent, Grade 1 is Noticeable, Grade 2 is Bothersome but not preventing activity, and Grade 3 is Bothersome and interfering with activities. TSS is derived daily by summing of the 13 observed symptom grade values from Day 1 through Day 14 to generate the curve for analysis. Day 1 through Day 14
Secondary RSV RNA Viral Load Area Under the Curve (AUC) RSV RNA viral load as measured in nasopharyngeal swab samples by RT-qPCR on Days 1 (Baseline, time 0), 3, 5, 9, and 14 to generate curve for analysis. Day 1 through Day 14
Secondary Number of Subjects With RSV RNA Viral Load Below Limit of Detection (LOD) Proportion of patients that have undetectable RSV RNA by qRT-PCR at Days 3, 5, 9 and 14. Days 3, 5, 9 and 14
Secondary Number of Participants With Adverse Events Day 1 through Day 14
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04528719 - A Dose Escalation Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1345 in Healthy Adults and in Children Who Are Respiratory Syncytial Virus (RSV)-Seropositive Phase 1
Terminated NCT02508194 - A Study to Evaluate the Efficacy of MEDI7510 in Older Adults Phase 2
Active, not recruiting NCT06060457 - A Study to Evaluate the Safety and Immune Response of mRNA-1345, a Vaccine Targeting Respiratory Syncytial Virus (RSV), When Co-administered With a Fluzone HD, in Adults ≥65 Years of Age Phase 3
Terminated NCT01757496 - Cough Assist in Bronchiolitis N/A
Completed NCT00100373 - RSV Challenge in Healthy Adults N/A
Completed NCT03524118 - Safety, Tolerability, and Pharmacokinetics of Clesrovimab (MK-1654) in Infants (MK-1654-002) Phase 1/Phase 2
Active, not recruiting NCT05572658 - Moderna Vaccine mRNA-1345 Observational Respiratory Syncytial Virus (RSV) Study
Recruiting NCT06067230 - A Study to Investigate the Immunogenicity and Safety of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in High-risk Adults Phase 3
Completed NCT00246480 - RSV Disease in the Elderly
Active, not recruiting NCT06097299 - A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus Phase 2
Completed NCT00889070 - Respiratory Events Among Premature Infants N/A
Unknown status NCT00613184 - Comparison of Nylon Flocked Swabs and Saline Aspirates for Detection Respiratory Viruses N/A
Completed NCT05559905 - Respiratory Syncytial Virus (RSV) Human Challenge Study of Molnupiravir in Healthy Participants (MK-4482-017) Phase 2
Active, not recruiting NCT05127434 - A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥60 Years of Age Phase 2/Phase 3
Terminated NCT04978337 - A Study of Rilematovir (JNJ-53718678) in Adult Outpatients With Respiratory Syncytial Virus (RSV) Infection Phase 2
Recruiting NCT06143046 - A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus in Pregnant Women and in Infants Born to Vaccinated Mothers Phase 2
Active, not recruiting NCT05397223 - A Study of Modified mRNA Vaccines in Healthy Adults Phase 1
Completed NCT02472548 - A Study to Evaluate the Safety and Reactogenicity of DPX-RSV(A), a Respiratory Syncytial Virus Vaccine Phase 1
Completed NCT01734668 - Sofia RSV FIA Field Study N/A
Completed NCT01562938 - MEDI-557 Adult Dosing Phase 1